Track Molbio Diagnostics Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 16.58 %
Low
1,012.0
High
1,219.9
1 Month returns: –
1 Year returns: –
3 Year CAGR: –
5 Year CAGR: –
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Molbio Diagnostics Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Molbio Diagnostics Ltd. Shareholding Pattern
Quarterly breakdown of Molbio Diagnostics Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Molbio Diagnostics Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Molbio Diagnostics Ltd.?
The current share price of Molbio Diagnostics Ltd. is ₹ 1,208.10 as of 24 Aug 2026.
What is the market capitalisation of Molbio Diagnostics Ltd.?
The market capitalisation of Molbio Diagnostics Ltd. stands at ₹ 12,658.50 Cr.
What is the PE ratio of Molbio Diagnostics Ltd.?
The Price-to-Earnings (PE) ratio of Molbio Diagnostics Ltd. is - as of the latest trailing twelve months data.
What is the ROE and ROCE of Molbio Diagnostics Ltd.?
Molbio Diagnostics Ltd. has a Return on Equity (ROE) of - and a Return on Capital Employed (ROCE) of - as per the latest financial reports.
What is the 52-week high and low of Molbio Diagnostics Ltd.?
The 52-week high of Molbio Diagnostics Ltd. is - and the 52-week low is -.
What is the dividend yield of Molbio Diagnostics Ltd.?
The dividend yield of Molbio Diagnostics Ltd. is - based on the current market price.
What is the FII and DII holding in Molbio Diagnostics Ltd.?
Foreign Institutional Investors (FII) hold 1.51%, Domestic Institutional Investors (DII) hold 3.68% and retail/public investors hold 40.06% of Molbio Diagnostics Ltd. shares.
What sector does Molbio Diagnostics Ltd. belong to?
Molbio Diagnostics Ltd. operates in the Healthcare sector.
What is the beta of Molbio Diagnostics Ltd.?
The beta of Molbio Diagnostics Ltd. is -, indicating its price volatility relative to the broader market.
What is the RSI of Molbio Diagnostics Ltd.?
The 14-day Relative Strength Index (RSI) of Molbio Diagnostics Ltd. is -. An RSI above 70 is considered overbought and below 30 is considered oversold.
1,208.10109.6 (9.98%)
16.58% since 17 Aug 2026
No corporate action data available.
Jun 2026
Aug 2026
Total Promoter
-
41.29
Indian Promoter
-
41.29
Foreign Promoter
-
-
Institutions
-
17.88
Mutual Funds / UTI
-
2.25
FI/Bank/Insurance
0.00
1.43
Govt
-
-
FII
0.00
1.51
Other Institutions
0.00
12.70
Non-Institution
-
40.82
Bodies Corporate
-
0.76
Others (incl. Retail)
No. of shareholders
0.00
0
40.06
2,33,303
Stock Analysis
Fundamental analysis overview of Molbio Diagnostics Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Not enough talking points with positive stance
Negative
Stock is fairly expensive with negative EPS on a trailing 12-month basis
Earnings yield of nan% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis
What is Earnings yield (E/P)?
Weak price momentum
Price Momentum score of 28.7 indicates that the stock has weak price momentum. Research has shown that stocks with lower momentum continue to underperform in the near term
What is Price Momentum score?
28.7 / 100
Neutral
Not enough talking points with neutral stance
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Not enough data
Profit After Tax FY
Not enough data
ROE FY
Not enough data
EBITDA FY
Not enough data
Name
Date
Type
Price
Qty.
Value
NK SECURITIES RESEARCH PRIVATE LIMITED
17 Aug 2026
buy
₹ 990.82
5.80 lac
₹ 57.46 cr
NK SECURITIES RESEARCH PRIVATE LIMITED
17 Aug 2026
sell
₹ 991.34
5.80 lac
₹ 57.49 cr
Company Profile
Overview of Molbio Diagnostics Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Molbio Diagnostics Limited is a point-of-care diagnostics company. The Company is engaged in the business of manufacturing chip based diagnostic devices, chips and reagents, X-radiation equipment, single/dual detector solutions, developing diagnostic devices, performing tests in the bio-sensing domain, digital pathology, among others. Its solutions include Truenat, Truenat Assays, iBreastExam, ProRad Atlas Ultraportable and Optra Scan. Truenat is a novel multi-disease real-time PCR platform. Truenat enables evidence-based treatment decisions for numerous infectious and communicable diseases such as tuberculosis, HIV, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza (including H1N1), HPV high-risk (HPV HR), cholera, and leprosy, along with non-infectious markers such as HLA-B27. The ProRad Atlas Ultraportable is an AI-powered, ultraportable digital X-Ray system designed for imaging in various settings, including home healthcare, mobile health camps, and remote areas.
Molbio Diagnostics Limited is a point-of-care diagnostics company. The Company is engaged in the business of manufacturing chip based diagnostic devices, chips and reagents, X-radiation equipment, single/dual detector solutions, developing diagnostic devices, performing tests in the bio-sensing doma...